{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:00:21Z","timestamp":1773316821066,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejmech.2021.113782","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T13:13:31Z","timestamp":1629206011000},"page":"113782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT1F receptor agonists for migraine therapy"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-9530","authenticated-orcid":false,"given":"Chuanfei","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhe","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zusheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113782_bib1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(97)11370-8","article-title":"Migraine","volume":"351","author":"Ferrari","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113782_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1526-4610.2001.041007638.x","article-title":"Migraine diagnosis and treatment: results from the American migraine study II","volume":"41","author":"Lipton","year":"2001","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2021.113782_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","article-title":"Migraine\u2014current understanding and treatment","volume":"346","author":"Goadsby","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113782_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.159.8.813","article-title":"Burden of migraine in the United States disability and economic costs","volume":"159","author":"Hu","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejmech.2021.113782_bib5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archneurpsyc.1938.02270040093005","article-title":"Mechanism of migraine headache and the action of ergotamine tartrate","volume":"39","author":"Graham","year":"1938","journal-title":"Arch. Neurol. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.113782_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1474-4422(09)70090-0","article-title":"Origin of pain in migraine: evidence for peripheral sensitisation","volume":"8","author":"Olesen","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2021.113782_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-physiol-030212-183717","article-title":"Pathophysiology of migraine","volume":"75","author":"Daniela","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ejmech.2021.113782_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia : an international journal of headache"},{"key":"10.1016\/j.ejmech.2021.113782_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2021.113782_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/B978-0-12-013317-8.50008-3","article-title":"The pharmacology and therapeutic potential of serotonin receptor agonists and antagonists","volume":"17","author":"Fuller","year":"1988","journal-title":"Adv. Drug Res."},{"key":"10.1016\/j.ejmech.2021.113782_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0028-3908(86)90207-8","article-title":"Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine","volume":"25","author":"Bradley","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2021.113782_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/0166-2236(88)90011-2","article-title":"5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization","volume":"11","author":"Peroutka","year":"1988","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejmech.2021.113782_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2165\/00003495-199447040-00006","article-title":"Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache","volume":"47","author":"Plosker","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113782_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","article-title":"Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of A meta-analysis of 53 trials","volume":"22","author":"Ferrari","year":"2002","journal-title":"Cephalalgia : an international journal of headache"},{"key":"10.1016\/j.ejmech.2021.113782_bib15","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.2165\/11537990-000000000-00000","article-title":"Triptans for the management of migraine","volume":"70","author":"Johnston","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113782_bib16","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","article-title":"Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy","volume":"60","author":"Tfelt-Hansen","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113782_bib17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0140-6736(93)92449-4","article-title":"Adverse reactions associated with sumatriptan","volume":"341","author":"Luman","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113782_bib18","first-page":"563","article-title":"Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine","volume":"62","author":"Dodick","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2021.113782_bib19","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT1B\/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113782_bib20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2021.113782_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies-successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2021.113782_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nurt.2010.03.003","article-title":"5-HT1F receptor agonists: a new treatment option for migraine attacks?","volume":"7","author":"Neeb","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2021.113782_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","article-title":"Targeted 5-HT1F therapies for migraine","volume":"15","author":"Vila-Pueyo","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2021.113782_bib24","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","article-title":"Acute migraine: can the new drugs clinically outpace?","volume":"2","author":"Singh","year":"2020","journal-title":"SN Comprehensive Clinical Medicine"},{"key":"10.1016\/j.ejmech.2021.113782_bib25","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113782_bib26","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2021.113782_bib27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0333102410388435","article-title":"44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study","volume":"31","author":"Diener","year":"2011","journal-title":"Cephalalgia : an international journal of headache"},{"key":"10.1016\/j.ejmech.2021.113782_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107528","article-title":"Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans","volume":"211","author":"de Vries","year":"2020","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113782_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14737175.2021.1912599","article-title":"Lasmiditan: an additional therapeutic option for the acute treatment of migraine","volume":"21","author":"Martinelli","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2021.113782_bib30","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1021\/jm030020m","article-title":"Novel potent 5-HT1F receptor agonists: structure-activity studies of a series of substituted N-[3-(1-Methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides","volume":"46","author":"Filla","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113782_bib31","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1021\/jm0155190","article-title":"N-[3-(2-Dimethylaminoethyl)-2-methyl-1H-indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT1F receptor agonist potentially useful for migraine therapy","volume":"44","author":"Xu","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113782_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bmcl.2003.09.091","article-title":"Substituted furo[3,2-b]pyridines: novel bioisosteres of 5-HT1F receptor agonists","volume":"14","author":"Mathes","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113782_bib33","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.bmcl.2004.09.079","article-title":"Design, synthesis and evaluation of bicyclic benzamides as novel 5-HT1F receptor agonists","volume":"14","author":"Zhang","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113782_bib34","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1021\/jm7011722","article-title":"Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide","volume":"51","author":"Choi","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113782_bib35","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113782_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jfluchem.2006.06.007","article-title":"Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules","volume":"127","author":"Kirk","year":"2006","journal-title":"J.\u00a0Fluor. Chem."},{"key":"10.1016\/j.ejmech.2021.113782_bib37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1039\/B610213C","article-title":"Fluorine in medicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2021.113782_bib38","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1021\/jm800219f","article-title":"The many roles for fluorine in medicinal chemistry","volume":"51","author":"Hagmann","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113782_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0270(98)00010-7","article-title":"A\u00a0fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation","volume":"81","author":"Johnson","year":"1998","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.ejmech.2021.113782_bib40","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejmech.2021.113782_bib41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.bjp.0703587","article-title":"Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT1F receptor agonists and PGF2\u03b1","volume":"131","author":"Cohen","year":"2000","journal-title":"Br. J. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421006310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421006310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:32:02Z","timestamp":1759329122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421006310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"alternative-id":["S0223523421006310"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113782","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT1F receptor agonists for migraine therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113782"}}